SCHEMBL3082128

SCHEMBL3082128

O=C(O)c1cccc(F)c1CCc1cccc2ccccc12

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MCL1 Q07820 4/20 0.54
▸ NR4A1 P22736 1/20 0.51
▸ NR4A2 P43354 1/20 0.51
▸ NR4A3 Q92570 1/20 0.51
▸ DHODH Q02127 1/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ HPGD P15428 2/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ LMNA P02545 1/20 0.49
▸ PTGER4 P35408 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ MC4R P32245 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.47
▸ CDC25B P30305 1/20 0.46
▸ COPS5 Q92905 1/20 0.46
▸ POLB P06746 1/20 0.45
▸ MTNR1A P48039 2/20 0.44
▸ SLC16A3 O15427 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13725011 0.87 MC4R (0.47) MCL1DHODHMEN1KMT2AHPGD
SCHEMBL16559363 0.86 ALB (0.49) MEN1KMT2AHPGDKDM4E
SCHEMBL11186472 0.83 NR4A1 (0.63) MCL1NR4A1NR4A2NR4A3MEN1
SCHEMBL3093429 0.78 MC4R (0.54) MCL1MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL15271550 0.75 NR4A1 (0.53) MCL1NR4A1NR4A2NR4A3DHODH
SCHEMBL8676722 0.75 HTR1A (0.55) MEN1KMT2ALMNAPTGER4
SCHEMBL31289 0.75 ALB (0.53) HPGDKDM4ELMNA
SCHEMBL27541315 0.74 NR4A1 (0.51) MCL1NR4A1NR4A2NR4A3MEN1
SCHEMBL27631073 0.73 ALB (0.52) MEN1KMT2AHPGDKDM4E
SCHEMBL29946543 0.72 KDM4E (0.56) MCL1NR4A1NR4A2NR4A3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790719-B2 Modulators of melanocortin receptor ORE PHARMACEUTICALS, INC. (US) 2010-09-07 — — US disclosed
US-7790719-B2 Modulators of melanocortin receptor ORE PHARMACEUTICALS, INC. (US) 2010-09-07 — — US disclosed
US-7790719-B2 Modulators of melanocortin receptor ORE PHARMACEUTICALS, INC. (US) 2010-09-07 — — US disclosed
EP-1590338-B1 MODULATORS OF MELANOCORTIN RECEPTOR ORE PHARMACEUTICALS INC (US) 2009-08-26 — — EP disclosed
US-7365070-B2 Modulators of melanocortin receptor ORE PHARMACEUTICALS INC. (US) 2008-04-29 — — US disclosed
US-7365070-B2 Modulators of melanocortin receptor ORE PHARMACEUTICALS INC. (US) 2008-04-29 — — US disclosed
US-7365070-B2 Modulators of melanocortin receptor ORE PHARMACEUTICALS INC. (US) 2008-04-29 — — US disclosed
US-20070293498-A1 Modulators of melanocortin receptor GENE LOGIC, INC. (US) 2007-12-20 — — US disclosed
US-20070293498-A1 Modulators of melanocortin receptor GENE LOGIC, INC. (US) 2007-12-20 — — US disclosed
US-20070293498-A1 Modulators of melanocortin receptor GENE LOGIC, INC. (US) 2007-12-20 — — US disclosed
EP-1590338-A2 MODULATORS OF MELANOCORTIN RECEPTOR Gene Logic Inc. (US) 2005-11-02 — — EP disclosed
US-20040147746-A1 Modulators of melanocortin receptor MILLENNIUM PHARMACEUTICALS, INC. 2004-07-29 — — US disclosed
WO-2004050610-A2 MODULATORS OF MELANOCORTIN RECEPTOR GENE LOGIC INC. (US) 2004-06-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293498-A1 Modulators of melanocortin receptor MC4R, MC1R, MC5R MCL1 631/4885NR4A1 446/4885NR4A2 519/4885
US-20040147746-A1 Modulators of melanocortin receptor MC1R, MC3R, MC5R MCL1 514/4885NR4A1 606/4885NR4A2 798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback